Application of phaffia rhodozyma astaxanthin in preparing medicament for preventing and controlling type II diabetes

A technology of Phaffia rhodozyma and diabetes medicine, which is applied in the field of application of Phaffia rhodozyme astaxanthin in the preparation of drugs for preventing and treating type Ⅱ diabetes

Inactive Publication Date: 2008-12-03
ZHEJIANG UNIV OF TECH
View PDF1 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] At present, there is no report on the application of microbial source Ph

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0013] Example 1: Preparation of Phaffia rhodozyma astaxanthin (see CN03117031.5)

[0014] Add 0.5% (w / w) calcium chloride and 0.5% (w / w) potassium phosphate to the fermented liquid of Phaffia rhodozyme, stir and react to generate calcium phosphate precipitate, and at the same time make the yeast cells coagulate and precipitate together; then add 0.1% (w / w) polyacrylamide, stirring to flocculate the precipitate and form more precipitate. The precipitate was centrifuged and separated by a continuous decanter centrifuge to obtain a wet Phaffia rhodozyme cell (containing 225 μg / g astaxanthin).

[0015] Add 500 L of acetic acid and 1 kg of butyl hydroxytetraphenyl (HBT) to 100 kg of Phaffia rhodozyma wet cells, stir to disperse the cells evenly, then keep warm at 50-60°C for 5 hours, filter with plate and frame, and wash with water to obtain The initial astaxanthin extract (organic phase containing astaxanthin) was 624L, and the content of astaxanthin was 33 μg / mL.

[0016] Add ...

Embodiment 2

[0018] Using 100-110 g male Wistar rats as experimental animals, a type II diabetes model animal induced by high-fat and high-sugar diet combined with STZ injection was constructed. Add 110mg / kg feed (in terms of pure astaxanthin) of the Phaffia rhodozyma astaxanthin concentrate of Example 1 while feeding high-fat and high-sugar feed to induce diabetes, and the control group is fed with normal feed while inducing diabetes. After 6 weeks, the effects of biochemical indicators and related gene expressions in the blood and tissues of the rats were detected. Experiments have found that astaxanthin can improve blood glucose (GLU), total cholesterol (TC) and triglyceride (TG) indicators to a certain extent; adding astaxanthin to high-fat and high-sugar feed can increase adipoR1 and The expression level of adipoR2 (increased by about 1 times), and the expression of these two genes in muscle tissue decreased significantly after feeding high-fat and high-sugar diet for 6 weeks. In add...

Embodiment 3

[0020] Normal Wistar rats were fed with high-fat and high-sugar feed for 4 weeks, and the formation of type II diabetes was induced by intraperitoneal injection of 45mg / kg of streptozotocin (STZ), and then added with 110mg / kg (with pure astaxanthin) in the normal feed In Example 1, Phaffia rhodozyma astaxanthin concentrate was fed to the diseased rats, and the diabetic control group was fed with normal feed, and various indicators were detected after 3 weeks. The results showed that astaxanthin can reduce blood sugar by about 30%. At the same time, astaxanthin significantly up-regulated the gene expression levels of adipoR1, adipoR2, and UCP2 in the liver of diabetic rats, which were increased by 3.2, 2.8, and 5.1 times compared with the diabetic control group. It also increased the gene expression level of PPARγ about 1-fold. Astaxanthin significantly decreased the expression of adipoR1 in the adipose tissue of diabetic rats by about 60%. At the same time, the gene expressio...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides an application of microbial source phaffia rhodozyma astaxanthin in preparation of medicines for preventing and curing type II diabetes mellitus. Experiments show that the phaffia rhodozyma astaxanthin has good functions of preventing and curing type II diabetes mellitus and can be used to prepare the medicines for preventing and curing type II diabetes mellitus. In particular, the phaffia rhodozyma astaxanthin can be used to prepare medicines for reducing individual blood sugar of type II diabetes mellitus, or medicines for preventing individual insulin resistance to type II diabetes mellitus. The application has the advantages that: the invention provides an application of microbial source astaxanthin, namely phaffia rhodozyma astaxanthin in the preparation of medicines for preventing and curing type II diabetes mellitus and provides a foundation for development of new drugs.

Description

(1) Technical field [0001] The invention relates to the application of microbial source Phaffia rhodozyma astaxanthin in the preparation of drugs for preventing and treating type II diabetes. (2) Background technology [0002] Astaxanthin (3,3′-dihydroxy-β,β′-carotene-4,4′-dione), belongs to ketone carotenoids, the molecular formula is C 40 h 52 o 4 , the relative molecular weight is 596.86. Astaxanthin is a non-vitamin A-sourced ketone carotenoid that cannot be converted into vitamin A in animals, but it has strong antioxidant properties. The results of animal experiments show that astaxanthin has various biological properties such as inhibiting tumorigenesis and enhancing immune function. However, there are relatively few reports on the biological characteristics of natural astaxanthin derived from the microorganism Phaffia rhodozyma (Phaffiarhodozyma). At present, although the research and development of microbial source astaxanthin in China has started, and has pass...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/122A61P3/10
Inventor 傅正伟靳远祥王慧洁
Owner ZHEJIANG UNIV OF TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap